Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial
Authors' conclusion
In patients with JIA receiving tofacitinib, JADAS10-CID and ACR-CID rates improved rapidly and were sustained over time, and a small proportion of patients achieved JADAS10 remission.
Study context
- Population
- Patients with active juvenile idiopathic arthritis (JIA) (polyarticular-course JIA, PsA, or enthesitis-related arthritis); part 2 randomised those achieving American College of Rheumatology (ACR) improvement ≥ 30%173 randomised in part 2
- Participants
- 225 patients
- Comparison
- Continued tofacitinib vs switch to placebo
- Primary endpoint
- Rates of JADAS10-CID (2021 polyarthritis thresholds, CRP-based), JADAS10 remission (≥ 24 continuous weeks of JADAS10-CID), ACR-CID and ACR clinical remission
- Follow-up
- Week 44
Methodological detailsrandomized withdrawal, open-label part 1 (weeks 0-18), part 2 (weeks 18-44) randomized
- Randomized withdrawal
- Open-label part 1 (weeks 0-18)
- Part 2 (weeks 18-44) randomized
Primary result
As reported in the abstract
JADAS10-CID
Further findings
ACR-CID · week 44
JADAS10 remission · week 44
JADAS10-CID and ACR CID (ACR-CID), open-label tofacitinib (part 1) · week 18
- JADAS10-CID
- 30.5%
- ACR-CID
- 15.8%
Original publication
Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial. J Rheumatol. Published 1 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →